结直肠癌肝转移患者选择性内放射治疗后基于90Y-PET/CT的剂量学预测结局
本研究纳入24例仅肝转移的化疗难治性结直肠癌患者,行SIRT前后FDG-PET/CT及SIRT后90Y-PET/CT,对57个可评估病灶行基于体素的三维剂量学分析。病灶平均吸收剂量与TLG下降的相关系数为0.82,ROC分析确定39 Gy和60 Gy两个病灶剂量截断值分别预测非代谢缓解和高代谢缓解。所有病灶Dmean>39 Gy的患者OS为13个月,至少一个病灶Dmean<39 Gy的患者OS为5个月(p=0.012;HR 2.6,95%CI 0.98-7.00)。
要点
- SIRT后90Y-PET/CT病灶平均吸收剂量与FDG-PET/CT代谢缓解相关,相关系数0.82。
- 病灶Dmean截断值39 Gy预测非代谢缓解,灵敏度80%、特异度95%。
- 所有病灶Dmean>39 Gy者OS 13个月,至少一个病灶<39 Gy者OS 5个月。
核心结论
- 在化疗难治性mCRC患者中,SIRT后90Y-PET/CT测定的病灶Dmean与代谢缓解相关,较高的病灶Dmean与较长的OS相关。
研究设计与样本
- 24例仅肝转移的化疗难治性mCRC患者接受SIRT,行SIRT前后FDG-PET/CT及SIRT后90Y-PET/CT,共57个可评估病灶纳入分析。
- 在SIRT前后FDG-PET/CT上勾画病灶,按TLG下降分为非代谢缓解(TLG下降<15%)和高代谢缓解(TLG下降≥50%),并将勾画投影至解剖配准的90Y-PET/CT上行基于体素的三维剂量学。
- 采用ROC分析确定预测非代谢缓解和高代谢缓解的病灶Dmean截断值,并按所有病灶Dmean是否均>Dmean-under-treated分为“治疗充分”组和“治疗不充分”组,用Kaplan-Meier法描述OS曲线。
主要发现
- 57个可评估mCRC病灶中,病灶Dmean与TLG下降的相关系数为0.82。
- 预测非代谢缓解的病灶Dmean截断值为39 Gy(灵敏度80%、特异度95%、阳性预测值86%、阴性预测值92%)。
- 预测高代谢缓解的病灶Dmean截断值为60 Gy(灵敏度70%、特异度95%、阳性预测值96%、阴性预测值63%)。
- 所有病灶Dmean>39 Gy的患者OS为13个月,至少一个病灶Dmean<39 Gy的患者OS为5个月(p=0.012;HR 2.6,95%CI 0.98-7.00)。
关键数值与推荐
- 非代谢缓解定义为TLG下降<15%,高代谢缓解定义为TLG下降≥50%。
- 预测非代谢缓解的病灶Dmean截断值为39 Gy,灵敏度80%、特异度95%、阳性预测值86%、阴性预测值92%。
- 预测高代谢缓解的病灶Dmean截断值为60 Gy,灵敏度70%、特异度95%、阳性预测值96%、阴性预测值63%。
- 治疗不充分定义为至少一个病灶Dmean<39 Gy,治疗充分定义为所有病灶Dmean>39 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this work was to confirm that post-selective internal radiation therapy (SIRT) 90Y-PET/CT-based dosimetry correlates with lesion metabolic response and to determine its correlation with overall survival (OS) in liver-only metastases from colorectal cancer (mCRC) patients treated with SIRT. Twenty-four mCRC patients underwent pre/post-SIRT FDG-PET/CT and post-SIRT 90Y-PET/CT. Lesions delineated on pre/post-SIRT FDG-PET/CT were classified as non-metabolic responders (total lesion glycolysis (TLG)-decrease < 15%) and high-metabolic responders (TLG-decrease ≥ 50%). Lesion delineations were projected on the anatomically registered 90Y-PET/CT. Voxel-based 3D dosimetrywas performed on the 90Y-PET/CT and lesions' mean absorbed dose (Dmean) was measured. The coefficient of correlation between Dmean and TLG-decrease was calculated. The ability of lesion Dmean to predict non-metabolic response and high-metabolic response was tested and two cutoff values (Dmean-under-treated and Dmean-well-treated) were determined using ROC analysis. Patients were dichotomised in the "treated" group (all the lesions received a Dmean > Dmean-under-treated) and in the "under-treated" group (at least one lesion received a Dmean < Dmean-under-treated). Kaplan-Meier product limit method was used to describe OS curves. RESULTS: Fifty-seven evaluable mCRC lesions were included. The coefficient of correlation between Dmean and TLG-decrease was 0.82. Two lesion Dmean cutoffs of 39 Gy (sensitivity 80%, specificity 95%, predictive-positive-value 86% and negative-predictive-value 92%) and 60 Gy (sensitivity 70%, specificity 95%, predictive positive-value 96% and negative-predictive-value 63%) were defined to predict non-metabolic response and high-metabolic response respectively. Patients with all lesions Dmean> 39 Gy had a significantly longer OS (13 months) than patients with at least one lesion Dmean < 39 Gy (OS = 5 months) (p = 0.012;hazard-ratio, 2.6 (95% CI 0.98-7.00)). CONCLUSIONS: In chemorefractory mCRC patients treated with SIRT, lesion Dmean determined on post-SIRT 90Y-PET/CT correlates with metabolic response and higher lesion Dmean is associated with prolonged OS.
引用
- Levillain H, Duran Derijckere I, Marin G, et al. 90Y-PET/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer. EJNMMI Res. 2018. PMID: 30006851. doi:10.1186/s13550-018-0419-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。